Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33910421)

  • 1. Tumor Suppressor Effect of RBMS3 in Breast Cancer.
    Wang C; Wu Y; Liu Y; Pan F; Zeng H; Li X; Yu L
    Technol Cancer Res Treat; 2021; 20():15330338211004921. PubMed ID: 33910421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of RBMS3 predicts a favorable prognosis in human gallbladder carcinoma.
    Wu Y; Meng D; You Y; Sun R; Yan Q; Bao J; Sun Y; Yun D; Li Y; Sun D
    Oncol Rep; 2020 Jul; 44(1):55-68. PubMed ID: 32627033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer.
    Wu Y; Yun D; Zhao Y; Wang Y; Sun R; Yan Q; Zhang S; Lu M; Zhang Z; Lu D; Li Y
    Oncotarget; 2017 Jan; 8(1):1262-1277. PubMed ID: 27902480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBMS3 is a tumor suppressor gene that acts as a favorable prognostic marker in lung squamous cell carcinoma.
    Liang YN; Liu Y; Meng Q; Li X; Wang F; Yao G; Wang L; Fu S; Tong D
    Med Oncol; 2015 Feb; 32(2):459. PubMed ID: 25588924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RNA binding protein RBMS3 inhibits the metastasis of breast cancer by regulating Twist1 expression.
    Zhu L; Xi PW; Li XX; Sun X; Zhou WB; Xia TS; Shi L; Hu Y; Ding Q; Wei JF
    J Exp Clin Cancer Res; 2019 Feb; 38(1):105. PubMed ID: 30819235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of RBMS3 in Breast Cancer Progression.
    Górnicki T; Lambrinow J; Mrozowska M; Romanowicz H; Smolarz B; Piotrowska A; Gomułkiewicz A; Podhorska-Okołów M; Dzięgiel P; Grzegrzółka J
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
    Block CJ; Mitchell AV; Wu L; Glassbrook J; Craig D; Chen W; Dyson G; DeGracia D; Polin L; Ratnam M; Gibson H; Wu G
    Oncogene; 2021 Nov; 40(46):6430-6442. PubMed ID: 34608266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RBMS3 Inhibits the Proliferation and Metastasis of Breast Cancer Cells.
    Yang Y; Quan L; Ling Y
    Oncol Res; 2018 Jan; 26(1):9-15. PubMed ID: 28409548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive bioinformatics analysis confirms RBMS3 as the central candidate biological target for ovarian cancer.
    Wang M; Fu X; Wang W; Zhang Y; Jiang Z; Gu Y; Chu M; Shao Y; Li S
    Med Eng Phys; 2022 Dec; 110():103883. PubMed ID: 36075788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma.
    Li Y; Chen L; Nie CJ; Zeng TT; Liu H; Mao X; Qin Y; Zhu YH; Fu L; Guan XY
    Cancer Res; 2011 Oct; 71(19):6106-15. PubMed ID: 21844183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBMS3 at 3p24 inhibits nasopharyngeal carcinoma development via inhibiting cell proliferation, angiogenesis, and inducing apoptosis.
    Chen J; Kwong DL; Zhu CL; Chen LL; Dong SS; Zhang LY; Tian J; Qi CB; Cao TT; Wong AM; Kong KL; Li Y; Liu M; Fu L; Guan XY
    PLoS One; 2012; 7(9):e44636. PubMed ID: 22957092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low expression of RBMS3 and SFRP1 are associated with poor prognosis in patients with gastric cancer.
    Zhang T; Wu Y; Fang Z; Yan Q; Zhang S; Sun R; Khaliq J; Li Y
    Am J Cancer Res; 2016; 6(11):2679-2689. PubMed ID: 27904780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines.
    Wang YY; Gu XL; Wang C; Wang H; Ni QC; Zhang CH; Yu XF; Yang LY; He ZX; Mao GX; Yang SY
    Tumour Biol; 2016 Jul; 37(7):9755-69. PubMed ID: 26810065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer.
    Lei F; Zhang L; Li X; Lin X; Wu S; Li F; Liu J
    BMC Cancer; 2014 Jun; 14():457. PubMed ID: 24947166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1.
    Fritz D; Stefanovic B
    J Mol Biol; 2007 Aug; 371(3):585-95. PubMed ID: 17586524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
    Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
    J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.
    Mirza S; Rakha EA; Alshareeda A; Mohibi S; Zhao X; Katafiasz BJ; Wang J; Gurumurthy CB; Bele A; Ellis IO; Green AR; Band H; Band V
    Breast Cancer Res Treat; 2013 Feb; 137(3):721-31. PubMed ID: 23288344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
    Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of TP53INP1 gene expression in estrogen receptor α-positive breast cancer patients.
    Nishimoto M; Nishikawa S; Kondo N; Wanifuchi-Endo Y; Hato Y; Hisada T; Dong Y; Okuda K; Sugiura H; Kato H; Takahashi S; Toyama T
    Jpn J Clin Oncol; 2019 Jun; 49(6):567-575. PubMed ID: 30855679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.